StockData

Aspira Women's Health Inc. (AWHL) stock

AWHLOTCIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 1/30
$0.22−0.01 (-2.61%)

Close on Oct 19, 2026Market cap $9.91MP/E –Yield –

Aspira Women's Health r&d expenses

Research and development expenses are spending on new products and technology.

Aspira Women's Health's R&D Expenses for the twelve months ending Jun 30, 2026 was $3.12M, up 1.1% year over year. For fiscal 2025 it was $2.88M, down 11.9% from the year before. Over ten years it grew -2.6% a year on average. The highest annual figure on record is $5.92M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.88M-11.9%
FY2024Dec 31, 2024$3.27M-19.1%
FY2023Dec 31, 2023$4.04M-31.8%
FY2022Dec 31, 2022$5.92M+11.3%
FY2021Dec 31, 2021$5.31M+152.6%
FY2020Dec 31, 2020$2.10M+106.7%
FY2019Dec 31, 2019$1.02M+85.1%
FY2018Dec 31, 2018$550.00K-34.3%
FY2017Dec 31, 2017$837.00K-61.5%
FY2016Dec 31, 2016$2.17M-42.1%
FY2015Dec 31, 2015$3.75M-19.6%
FY2014Dec 31, 2014$4.67M+79.8%
FY2013Dec 31, 2013$2.60M+17.1%
FY2012Dec 31, 2012$2.22M-58.9%
FY2011Dec 31, 2011$5.39M+40.0%
FY2010Dec 31, 2010$3.85M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$692.00K-1.7%
Q1 FY2026Mar 31, 2026$1.23M+26.0%
Q4 FY2025Dec 31, 2025$462.00K-7.6%
Q3 FY2025Sep 30, 2025$739.00K-18.6%
Q2 FY2025Jun 30, 2025$704.00K-26.1%
Q1 FY2025Mar 31, 2025$973.00K+7.4%
Q4 FY2024Dec 31, 2024$500.00K-53.6%
Q3 FY2024Sep 30, 2024$908.00K-9.0%
Q2 FY2024Jun 30, 2024$952.00K+37.4%
Q1 FY2024Mar 31, 2024$906.00K-28.5%
Q4 FY2023Dec 31, 2023$1.08M+7.5%
Q3 FY2023Sep 30, 2023$998.00K-53.7%
Q2 FY2023Jun 30, 2023$693.00K-50.9%
Q1 FY2023Mar 31, 2023$1.27M-6.0%
Q4 FY2022Dec 31, 2022$1.00M-31.0%
Q3 FY2022Sep 30, 2022$2.16M+42.1%
Q2 FY2022Jun 30, 2022$1.41M-4.1%
Q1 FY2022Mar 31, 2022$1.35M+54.6%
Q4 FY2021Dec 31, 2021$1.45M+98.0%
Q3 FY2021Sep 30, 2021$1.52M+155.1%
Q2 FY2021Jun 30, 2021$1.47M+287.1%
Q1 FY2021Mar 31, 2021$872.00K+120.8%
Q4 FY2020Dec 31, 2020$734.00K+200.8%
Q3 FY2020Sep 30, 2020$595.00K+75.0%
Q2 FY2020Jun 30, 2020$380.00K+68.9%
Q1 FY2020Mar 31, 2020$395.00K+89.0%
Q4 FY2019Dec 31, 2019$244.00K+95.2%
Q3 FY2019Sep 30, 2019$340.00K+163.6%
Q2 FY2019Jun 30, 2019$225.00K+46.1%
Q1 FY2019Mar 31, 2019$209.00K+47.2%
Q4 FY2018Dec 31, 2018$125.00K-17.8%
Q3 FY2018Sep 30, 2018$129.00K-32.8%
Q2 FY2018Jun 30, 2018$154.00K-42.5%
Q1 FY2018Mar 31, 2018$142.00K-36.9%
Q4 FY2017Dec 31, 2017$152.00K-50.0%
Q3 FY2017Sep 30, 2017$192.00K-48.1%
Q2 FY2017Jun 30, 2017$268.00K–
Q1 FY2017Mar 31, 2017$225.00K–
Q4 FY2016Dec 31, 2016$304.00K–
Q3 FY2016Sep 30, 2016$370.00K–

More Aspira Women's Health figures

See a number that looks wrong?